Poster Session B

Poster Session B
Thursday, December 2
12:30 p.m.-2:30 p.m.

In alphabetical order, not board assignment order

Antibodies in Cancer Immunity
• Antibody responses in primary and metastatic melanoma. Panagiotis Karagiannis1, Amy Eileen Gilbert1, Luke Roberts1, Emma Beddowes1, David Fear2, Hannah J. Gould2, Katie Lacy1, Frank O. Nestle1, Sophia N. Karagiannis1. 1NIHR/BRC, St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, London, United Kingdom, 2Division of Asthma and Allergy, King's College London, London, United Kingdom.
• Intratumor checkpoint blockade mediates regression of local and distant tumors. Linda C. Sandin1, Sara M. Mangsbo1, Angelica SI Loskog1, Peter Ellmark2, Thomas H. Tötterman1. 1Uppsala University, Uppsala, Sweden, 2Lund University, Lund, Sweden.
• Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells. Tracy R. Daniels1, Rafaela Quintero1, Richard Leuchter1, Gustavo Helguera1, Jose A. Rodriguez1, Birgit C. Schultes2, Christopher F. Nicodemus2, Manuel L. Penichet1. 1University of California, Los Angeles, CA, 2Advanced Immune Therapeutics, Inc., Charlestown, MA.

Cancer Vaccines
• Higher avidity mesothelin-specific CD8+ T cell repertoires are associated with longer disease-free survival and tumor trafficking in patients treated with a GM-CSF-secreting pancreatic tumor vaccine. Eric R. Lutz, Jana-Lynn Louis, Guanglan Mo, Sara Solt, Lei Zheng, Daniel Laheru, Elizabeth M. Jaffee. Johns Hopkins University, Baltimore, MD.
• Immunotherapy against breast cancer targeting Stat3 triggers NK/CD4+ T cell-mediated antitumoral response and inhibits tumor growth in therapeutic administration. Mercedes Tkach1, Lorena Coria2, Cinthia Rosemblit1, Martin A. Rivas1, Wendy Beguelin1, Cecilia Proietti1, M Celeste Diaz Flaque1, Franco Izzo1, Eduardo H. Charreau1, Patricia V. Elizalde1, Juliana Cassataro2, Roxana Schillaci1. 1Instituto de Biología y Medicina Experimental, Buenos Aires, Argentina, 2IDEHU, Laboratorio de Inmunogenética, Hospital de Clínicas, Facultad de Medicina, UBA, Buenos Aires, Argentina.
• Results of phase I studies testing two live-attenuated listeria vaccines, ANZ-100 and CRS-207, for the treatment of cancer. Dung T. Le1, Ran Nir-Paz2, Johannes Hampl3, Shruti Mathur3, John Nemunaitis4, Daniel Sterman5, Raffit Hassan6, Peter Illei1, Eric Lutz1, Bentley Moyer3, Martin Giedlin3, Drew Pardoll1, Dirk Brockstedt3, Thomas Dubensky3, Joseph Eiden3, Elizabeth M. Jaffee1, Daniel A. Laheru1. 1Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD, 2Hadassah Hebrew-University Hospital, Jerusalem, Israel, 3Aduro Bio Tech, Berkeley, CA, 4Mary Crowley Cancer Center, Dallas, TX, 5Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, 6National Cancer Institute, Bethesda, MD.
• Role of regulatory T cells in immunization strategies involving recombinant alphavirus vector system. Mateusz Walczak, Joke Regts, Antoon J.M. van Oosterhout, Jan C. Wilschut, Hans W. Nijman, Toos Daemen. University Medical Center Groningen, Groningen, The Netherlands.
• Synergistic effect on survival of IFNγ- and IL-7 cell-based immunotherapy in the N32 rat glioma model. Sara Fritzell, Sofia Eberstål, Anna Darabi, Edward Visse, Peter Siesjö. Lund University, Lund, Sweden.
• The immune response to disialoganglioside GD3 vaccination in dogs with spontaneous occurring melanoma: A large animal translational model. Rowan J. Milner, James P. Farese, Marc E. Salute, Nick Bacon, Karri Barabas, Kelvin Kow, Shannon Lee Parfitt, Monica Clemente, Sarah Lyles, Christine Fahey. University of Florida, Gainesville, FL.
• The therapeutic effect on tumor-challenged mice of vaccinating with an adenovirus (Ad5) encoding a model tumor antigen (OVA) in combination with intratumoral doses of CpG ODN. Sean M. Geary1, Caitlin D. Lemke1, David M. Lubaroff2, Aliasger K. Salem1. 1College of Pharmacy, University of Iowa, Iowa City, IA, 2College of Medicine, University of Iowa, Iowa City, IA.
• Therapy and secondary prophylaxis of HPV-associated neoplasias based on recombinant chimeric constructs containing virus capsomeres and the p16INK4a antigen. Miriam Reuschenbach1, Franziska Faulstich1, Schädlich Lysann2, Hanna Seitz3, Madeleine Sauer1, Nicolas Wentzensen1, Kristina Nehls4, Andreas M. Kaufmann5, Elke Jäger6, Lutz Gissmann2, Magnus von Knebel Doeberitz1. 1Department of Applied Tumor Biology, University of Heidelberg, Heidelberg, Germany, 2Department of Genome Modifications and Carcinogenesis and 3Department of Tumorvirus-Specific Vaccination Strategies, German Cancer Research Center (DKFZ), Heidelberg, Germany, 4Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany, 5Division of Gynecologic Tumorimmunology, Department of Gynecology, Charite-Universitätsmedizin, Berlin, Germany, 6Hämatologie-Onkologie, Krankenhaus Nordwest, Frankfurt, Germany.

Combined Therapy
• Combination immunotherapy for melanoma. Bakulesh M. Khamar, Nirav M. Desai. Cadila Pharmaceuticals Ltd, Ahmedabad, Gujarat, India.
• Combination therapy using cromolyn and gemcitabine in long-acting liposomes for pancreatic cancer. Jin-Seok Kim, Jung-Hyun Kim, Min-Ji Koo, Cha-Eun Kim, Jae-Ha Ryu. Sookmyung Women's University, Seoul, Republic of Korea.
• Immunochemotherapy with 5-fluorouracil and interferon-α enhances recognition of tumor cells by NK and CD8+ T cells in orthotopic pancreatic cancer model. Hadeel Khallouf1, Susanne Serba2, Angela Märten3, Dirk Jäger4, Jan Schmidt2. 1University Hospital Heidelberg/ National Center for Tumor Diseases, Heidelberg, Germany, 2University Hospital Heidelberg, Heidelberg, Germany, 3Boehringer Ingelheim, Ingelheim Am Rhein, Germany, 4National Center for Tumor Diseases, Heidelberg, Germany.
• Inherently drug-resistant GBM cancer stem cells have a distinct antigen profile from stem-like GBM cancer stem cells. Kate Broadley, Kathryn Farrand, Ian Hermans, Melanie J. McConnell. Malaghan Institute of Medical Research, Wellington, New Zealand.
• The peptide AF-16 facilitates drug distribution and improves access to cells in solid tumors by transiently lowering the raised interstitial fluid pressure. Hans-Arne Hansson1, Mohamed Al-Olama2, AnnaCarin Wallgren1, Bengt Andersson1, Kliment Gatzinsky2, Ragnar Hultborn3, Eva Jennische1, Alex Karlsson-Parra1, Stefan Lange1. 1Biomedicine, University of Gothenburg, Gothenburg, Sweden, 2Neurosurgery Department and 3Oncology Department, Sahlgrens University Hospital, Gothenburg, Sweden.

Epigenetic Regulation of Tumor Growth and Immune Recognition
• Generation of memory CD8+ T cells against tumor antigens is independent of CD62L. Abdel-Aziz Zidan, Alberto J. Montero, C.Marcela Diaz-Montero. University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL.

Harnessing the Immune System to Prevent and Fight Disease
• Differential infiltration of T and B lymphocytes in premalignant and malignant lesions of the lip. Isolde Gina Rojas, Alejandra Martinez, Maria Loreto Spencer, Francisco Marchesani. School of Dentistry, University of Concepcion, Concepcion, Chile.
• Expansion and activation of CBMNC into natural killer (NK) cells with increased cytolytic activity both in vitro and in vivo: Potential for cancer cellular immunotherapy. Janet Ayello1, Frances Zhao1, Jessica Hochberg2, Andrew Stier1, William Quish1, Lauren Tiffen1, Carmella Vandeven1, Baxi V. Laxmi1, Mitchell S. Cairo1. 1Columbia University, New York Presbyterian Hospital, Morgan Stanley Children's Hospital, New York, NY, 2Maria Farei Children's Hospital, New York Medical College, Valhalla, NY.
• Frontiers of cellular therapy in childhood cancer: Overcoming tumor escape by selective alloreactive T cells. Guenther HS Richter, Uwe Thiel, Stefan Burdach. Children’s Cancer Research Center and Department of Pediatrics, Klinikum rechts der Isar, TUM, Munich, Germany.
• In vivo generation of highly tumorigenic cells deficient in CXCL9/Mig expression is IFN-g-dependent. Marianne Petro, Anton Gorbachev. Cleveland Clinic, Cleveland, OH.
• Monitoring the antibody repertoire of melanoma patients harbors the potential to identify novel treatments for cancer. Amy E. Gilbert, Panagiotis Karagiannis, Tihomir Dodev, Katie Lacy, Debra Josesphs, Phillip Blower, Hannah J. Gould, James Spicer, Frank O. Nestle, Sophia N. Karagiannis, Alexander Koers. King's College, London, United Kingdom.
• Restoration of tumor immune surveillance via selective stimulation of DLL1-Notch signaling. Yuhui Huang, Mikhail M. Dikov, Luping Lin, Li Yang, David P. Carbone. Vanderbilt University, Nashville, TN.
• The immunomodulatory peptide SCV-07 requires tyrosine phosphatase activity for inhibition of STAT3 phosphorylation and signaling in the Jurkat T cell line. Jackie Papkoff1, Hyun-Ku Lee2, Gita Singh2, Sujay Singh2, Sriram Chitta2, Kody Andrew2, Payton Quintel2, Jonathan S. Rosenberg2, Cynthia W. Tuthill1. 1SciClone Pharmaceuticals, Inc., Foster City, CA, 2IMGENEX CORP., San Diego, CA.

Premalignant Lesions and Prevention
• Increased fibroblast density in actinic cheilitis and its association with markers of lip photodamage and photocarcinogenesis. Alejandra Martinez1, Yadira Boza1, Maria Loreto Spencer1, Maritza Flores2, Isolde Gina Rojas1. 1School of Dentistry, University of Concepcion, Concepcion, Chile, 2School of Medicine, University of Concepcion, Concepcion, Chile.

Regulation of Immune Responses in Cancer
• Analysis of dendritic cells in peripheral blood of hepatocellular carcinoma-Comprehensive relationship with clinical staging. Jin Sook Jeong1, Sang-young Han2, Jun O. Jin3, Jong Young Kwak3. Departments of 1Pathology, 2Internal Medicine, and 3Biochemistry, MRCCMT, Dong-A University, Busan, Republic of Korea.
• Autoimmune mechanisms in antitumor immunity. Jason Miksa, Esperanza Bas, Zhibin Chen. University of Miami School of Medicine, Miami, FL.
• B lymphocytes inhibit antitumor response in a murine EMT-6 tumor model by facilitating expansion of T regulatory cells. Yu Zhang1, Tamar Tadmor2, Yair Eliav1, Eckhard R. Podack1, Robert Levy1, Joseph D. Rosenblatt1. 1University of Miami Miller School of Medicine, Miami, FL, 2Bnai Zion Medical Center, Haifa, Israel.
• Characterization of the tumor microenvironment in the transgenic TH-MYCN model of neuroblastoma. Lena-Maria Carlson, Agnes Rasmuson, Lova Segerström, Baldur Sveinbjörnsson, Per Kogner. Karolinska Institutet, Stockholm, Sweden.
• Deletion of TGF-β receptor promotes mammary carcinoma progression by enhanced Th17 response. Sergey Novitskiy, Michael Pickup, Agnieszka Gorska, Philip Owens, Anna Chytil, Mary Aakre, Huiyun Wu, Yu Shyr, Harold Moses. Vanderbilt University, Nashville, TN.
• Immunogenic cell death induced by free or polymer-bound doxorubicin. Martina Kabesova1, Lubomir Kovar1, Tomas Etrych2, Jiri Strohalm2, Ondra Hovorka1, Karel Ulbrich2, Blanka Rihova1. 1Institute of Microbiology ASCR, v.v.i., Prague, Czech Republic, 2Institute of Macromolecular Chemistry AS CR, v.v.i., Prague, Czech Republic.
• Increased hepatic metastases are associated with upregulation of MMP12 and inflammatory cell infiltration in the microenvironment of steatohepatitis. Michael N. VanSaun1, Alisha M. Mendonsa1, In Kyu Lee2, Lynn M. Matrisian1, Lee Gorden1. 1Vanderbilt University, Nashville, TN, 2The Catholic University of Korea, Seoul, Republic of Korea.
• Macrophage-infiltrated ovarian tumors are enriched in extracellular matrix components and immune modulators and correlate with poor prognosis. Yan Ma, Amitabha Chaudhuri, Suzana Couto, Catherine Zhu, Hilary Clark. Genentech, Inc., South San Francisco, CA.
• Nitric oxide inhibition by mercaptoethylguanidine (MEG) enhances the immune response and decrease tumor burden of postimmunized rats with colon carcinoma metastasis in the liver. Wiaam Badn, Peter Siesjö, Hans Olov Sjogren. Institution for Clinical Sciences, Lund, Sweden.
• Peripheral T cell tolerance is reversed by blockade of B7-H1 (PD-L1)/CD80 interaction. Jang-June Park1, Ryusuke Omiya1, Yumiko Matsumura1, Yukimi Sakoda1, Atsuo Kuramasu1, Yingjia Liu1, Scott Strome1, Lieping Chen2, Koji Tamada1. 1Univerisity of Maryland, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD.
• Prostaglandin E2 is produced by neuroblastoma cells and induces cell proliferation and survival. Agnes Rasmuson1, Anna Kock1, Lena-Maria Carlson1, Jaione Simon SantaMaria2, Ole Martin Fuskevag2, John Inge Johnsen1, Per Kogner1, Baldur Sveinbjornsson2. 1Karolinska Institutet, Stockholm, Sweden, 2University of Tromsö, Tromsö, Norway.
• Radiation favors T regulatory cells. Dörthe Schaue1, Josephine A. Ratikan1, Evelyn L. Kachikwu2, Keisuke S. Iwamoto1, William H. McBride1. 1University of California, Los Angeles, CA, 2City of Hope, Duarte, CA.
• The different expression of regulatory T cells and Th17 cells in the sentinel lymph nodes and lung cancer tissue. Hye Ok Kim, Jae Young Moon, Hye Kyoung Choi, Jae Jeong Shim, Gyu Young Hur, Kyung Ho Kang, Sung Yong Lee, Hyun Koo Kim. Korea University Medical Center, Seoul, Republic of Korea.
• The regulation of the cytolytic function of natural killer cells on the MCF-7 human breast cancer cell line by iron. Xianpeng Jiang, Robert L. Elliott, Brian G. Barnett, Jonathan F. Head. Elliott-Elliott-Head Breast Cancer Research and Treatment Center, Baton Rouge, LA.
• The role of N-(2-hydroxypropyl) methacrylamide bound doxorubicin in phagocytosis of cancer cells by dendritic cells. Kovár L1., Etrych T.2, Kabešová M.1, Strohalm J.2, Hovorka O.1, Ulbrich K.2, Ríhová B.1 1Institute of Microbiology ASCR v.v.i., 2Institute of Macromolecular Chemistry ASCR v.v.i. Prague, Czech Republic, (lkovar@biomed.cas.cz)
• Tumor VEGF-C drives peritumoral lymphangiognesis and CCL21 expression to promote immune escape. Amanda Waite Lund, Amine Issa, Jacqueline D. Shields, Melody A. Swartz. Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland.
• Tumor-specific CD8+ T cell responses are accelerated and magnified by concomitant castration and regulatory T cell depletion. Shuai Tang, Miranda L. Moore, Purnima Dubey. Wake Forest University School of Medicine, Winston-Salem, NC.

Other
• A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway and its implications in myeloproliferative disorders. Ying Zheng,1 Hongwei Qin,1 Stuart J. Frank,1, 2 Luqin Deng,2 David W. Litchfield,3 Ayalew Tefferi,4 Animesh Pardanani,4 Etty N. Benveniste1. Departments of 1Cell Biology and 2Medicine, The University of Alabama at Birmingham, Birmingham, AL, 3Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada, 4Mayo Clinic, Rochester, MN.
• CD15, CD24, CD29, and CD133 as biomarkers in medulloblastomas. Anna C. M. Darabi, Edward Visse, Nils Stahl, Peter Siesjo. Clinical Sciences, Lund University, Lund, Sweden.
• Correlation among DDT, arsenic and lipid peroxidation levels in tissue and serum of cancer patients of Bihar, India. Akhileshwari Nath. Research Centre, Mahavir Cancer Sansthan, Phulwarisharif, Patna, India.
• Galectin-1 modulates tolerance in neuroblastoma. Rocío Soldati1, Elisa Berger1, Ana Zenclussen2, Gerhard Jorch1, Mariana Salatino3, Gabriel A. Rabinovich3, Stefan Fest1. 1Otto-von-Guericke University, Department of Pediatrics, Magdeburg, Germany, 2Otto-von-Guericke University, ExperimentalGynecology, Magdeburg, Germany, 3Instituto de Biología y Medicina Experimental, Laboratorio de Inmunopatología, Buenos Aires, Argentina.
• Global approach to tumor immunity: Network signatures of progression and survival. Trevor Clancy, Hovig Eivind. Oslo University Hospital, Oslo, Norway.